A limited biosynthetic conversion of some known anthracyclinones using a specific daunorubicin-nonproducing mutant provided four new anthracycline antibiotics: l-Hydroxy-10-methoxycarbonyl-1 3-deoxocarminomycin; 1 -hydroxy-1 3-deoxocarminomycin; 1 -hydroxyoxaunomycin and 6-deoxyoxaunomycin. Their isolation and purification from bioconversion broth, structural determination and antitumor activities against leukemic L1210cells are described.
Microbial conversion with anthracycline-nonproducing mutants is a useful means for obtaining new hybrid anthracyclines. Wehave obtained a number of new hybrid anthracyclines by bioconversion of natural anthracyclinones using biosynthetically blocked mutants of aclarubicin-producing Streptomyces galilaeus MA144 Ml and daunorubicin-producing Streptomyces coeruleorubidus ME-130 A4.r~6) Recently we have found an intensely potent anthracycline antibiotic oxaunomycin (1-0- daunosaminyl /?-rhodomycinone) in the culture broth ,of a blocked mutant of a new baumycin-producing Streptomyces sp. D788.7) Since it was 30-fold more cytotoxic against L1210 cell culture than its TV-dimethyl derivative betaclamycin T (7-0-rhodosaminyl /?-rhodomycinone), our attention was directed to the 7-0-daunosaminyl derivatives of other rhodomycinone aglycones such as /?-isorhodomycinone (/?-isoRMN) and a-citromycinone (a-CTN). Their corresponding 7-O-rhodosaminyl derivatives such as obelmycin A8) and yellamycin A9) have been isolated and evaluated biologically by us, but their 7-O-daunosaminyl derivatives have not been yet obtained.
In this paper we describe production of the target 7-0-daunosaminyl hybrid anthracyclines
1-hydroxyoxaunomycin and 6-deoxyoxaunomycin by bioconversion of /MsoRMNand a-CTNusing a specific daunorubicin (DRN)-nonproducing mutant.
Materials and Methods

Microbial Strain
A bioconversion strain used for 7-O-daunosaminylation was a DRN-nonproducing mutant strain OCT. 1992 OXA-4which was derived from new baumycin-producing Streptomyces sp. D788.1O) This strain was capable of daunosaminylating a precursor aglycone although at least two steps of DRNbiosynthesis were impaired. It was grown on YS slant agar (yeast extract 0.3%, soluble starch 1% and agar 1.5%, pH 7.5) and stored at 5°C until use.
Media and Seed Culture
Mediumfor seed culture was soluble starch 0.5%, glucose 0.5%, soybean meal 1.0%, yeast extract 0.1%, K2HPO4 0.1%, MgSO4-7H2O 0.1% and NaCl 0.3% in tap water (pH 7.5) (seed medium). Slant culture was inoculated into a 500-ml Erlenmeyer flask containing 100ml of seed medium and cultivation was carried out at 30°C for 2 days on a rotary shaker (200rpm). The seed culture was inoculated 5% into conversion medium which consisted of soluble starch 4.0%, maltose 2.0%, dry yeast 2.0%, soybean meal 2.0%, yeast extract 0.2%, NaCl 0.1%, MgSO4-7H2O 0.1%, CaCO3 0.2%, CuSO4-5H2O 0.0007%, FeSO4-7H2O 0.0001%, MnSO4-4H2O 0.0008% and ZnSO4-7H2O 0.0002% in tap water (pH 7.4).
Microbial Conversion
Preliminary biosynthetic conversion of natural aglycones was examined with 250-ml Erlenmeyer flasks containing 30ml each of conversion medium. Cultivation was carried out at 30°C on a rotary shaker (200rpm). After 3 days, a methanol solution of substrate aglycone (2mg/ml) was added to the culture to give a final concentration of 30^g/ml and the cultivation was continued for 4 additional days. A sample of 2ml was withdrawn at an appropriate time during a period of bioconversion and 2ml each of acetone and CHC13added. After agitation, the mixture was centrifuged and the solvent layer was evaporated to dryness. The residual pigments were analyzed by TLC or HPLC.
Rhodomycinone (RMN)-type aglycones such as e-RMN, £-RMN, e-isoRMN,^-isoRMN and a-CTN, and aklavinone (AKN) and e-pyrromycinone(PMN) were used in these bioconversion experiments. All of the former RMN-typeaglycones used were prepared from acid-treated culture broths of Streptomyces violaceus A262 and its blocked mutants.8'9) AKNand a-PMN were prepared by acid hydrolysis of Streptomyces galilaeus products, MA144Al and A2, respectively.1 1* A large-scale bioconversion for obtaining new hybrid anthracyclines was performed using four 30-liter jar fermenter containing 15 liters of conversion medium. Cultivation was carried out at 28°C with agitation of 350 rpm and aeration of 1 5 liters/minute. Substrate aglycone (e-isoRMN, /?-isoRMN or a-CTN) was fed to give a final concentration of 40jug/ml by addition of 150ml of the methanol solution after 3 days and the cultivation was continued for 4 additional days. The conversion broth was harvested and centrifuged. Products were extracted from the mycelial pellet with 5 liters of acetone. The acetone extract wasevaporated to about a half volume, adjusted to pH 3.5 with 6n HC1and washed with CHC13.The aqueous layer was then adjusted to pH 8.5 with 4n NaOHand extracted with CHC13.The extract was evaporated to a small volumeand an excess of ethyl ether wasadded to precipitate crude product.
Acid Hydrolysis Samples (about 1 mg) in 0.1 n HC1 were heated at 80°C for 30minutes and the component sugar and aglycone were determined by TLC as previously described.8) CHCI3-MeOH-HCOOH(40: 10: 1) and CHC13-MeOH-aqNH3 (50: 10: 1) for bioconversion tests and checks on process of isolation and purification, and rc-BuOH-AcOH-H2O (4 : 1 : 1) for sugar analysis and CHCI3 -MeOH(20 : 1) for aglycone analysis. Preparative TLC was performed using Silica gel PF254 plates (Merck Co.) with a solvent ofCHC13 -MeOH-H2O-AcOH-aqNH3(120: 50: 5 : 1 : 1). HPLCwas carried out on a Hitachi 655 liquid chromatographic apparatus with a reverse phase analytical column, A312 (ODS) (6 x 150 mm) (Yamamura Chemical Laboratories Co.). Mobile phase used was 35% CH3CN(pH 2.0, adjusted with coned H3PO4) and was run at a flow rate of 1.0ml/minute. Samples were dissolved in or diluted with the mobile phase and a 10/xl aliquot was injected. Detection was at 436nm for a-CTN bioconversion and at 495 nm for the other bioconversion using a visible light detector (SPD-6AV: Shimadzu Corporation). Melting points were determined on a Kofler hotstage microscope. UVspectra were determined on a Hitachi EPS 3T and IR spectra (KBr pellet) on a Hitachi EPI-GS spectrophotometer. XHand 13C NMR were recorded with a Jeol GX-400spectrometer at 400 and 100 MHz,respectively. Chemical shifts are expressed in S value (ppm) with TMSas an internal reference and coupling constants are given in / (Hz).
Mass spectra were recorded with a Hitachi M-80H or a Jeol JMS SX102A spectrometer. Specific rotations were determined on a Jasco DIP-181 Digital Polarimeter.
Results
Bioconversion of Some Natural Aglycones with Strain OXA-4
Streptomyces sp. D788 strain OXA-4 used for bioconversion was derived as a pigment-less nonproducing mutant from a DRN-blocked mutant strain RPM-5, which was damaged at a 10-decarboxylation step of precursor metabolite D788-1 (10-carboxy-13-deoxocarminomycin) in the DRN biosynthesis so that it accumulated D788-1 as a major metabolite with some minor metabolites (or by-products), D788-6 (10-methoxycarbonyl-13-deoxocarminomycin), D788-7 (10-hydroxy-13-deoxocarminomycin; oxaunomycin) and D788-1 1 (13-deoxocarminomycin) (dCM) in the culture broth.12) Thus, the capability of producing a pigmented aglycone molecule was lost in this strain, but that of daunosaminylating a precursor aglycone was still maintained with some limited biosynthetic modification activities on the aglycone moiety.
The bioconversion of several aglycones fed in growing culture of strain OXA-4was tested and the results are shown in Table 1 . Aglycones tested were AKN,a-PMN, e-RMN,e-isoRMN, jff-RMN and /7-isoRMN, and were fed to a 3-day old growing culture. After additional, 4-day cultivation, the conversion cultures were harvested and products were extracted with organic solvents and assayed by TLC and HPLC. Bioconversion ofAKNand £-RMNgave the same three products la~lc when examined by TLC. Further TLCand HPLCanalyses revealed that la~lc were identical to the anthracycline metabolite produced by parent strain RPM-5: D788-6, D788-ll and D788-7, respectively. These results were predictable since AKNand e-RMNare precursor aglycones in DRNbiosynthesis. 13) By analogy it was expected that bioconversion of £-PMN (1-hydroxy-AKN) or £-isoRMN (1-hydroxy-s-RMN) with strain OXA-4 would produce the corresponding 1-hydroxy analogs. In fact, feeding of these aglycones also gave both the same three products 2a~2c whose Rf values on TLCwere parallel to those of la~lc, respectively, with an acidic solvent. HPLCbehaviors were also similar for both groups. However, their spot colors on TLC were red for la~lc but purple for 2a~2c. Amongthem, 2c was produced in very poor yield, but it was found by HPLCand TLC analyses that 2c was identical to 4a, which was obtained by the /?-isoRMN bioconversion as described below.
On the other hand, the bioconversion of /J-RMN, /?-isoRMN or a-CTN which has a hydroxy group at C-10 in place of a methoxycarbonyl group gave only one product in either case. The product from /7-RMN, 3a, showed a red color spot on TLC. Single products 4a (purple) and 5a (yellow) were obtained from /MsoRMN(purple) and a-CTN (yellow), respectively. 3a was found to be identical to lc (D788-7;
7-0-daunosaminyl-/?-RMN) in complete accordance with their behaviors on TLC and HPLC. This showed that bioconversion of /?-RMN, but not e-RMN or AKN, with strain OXA-4 was stopped at a daunosaminylation step without any further biosynthetic modification of the aglycone. This bioconversion manner suggested that 4a and 5a were also 7-0-daunosaminyl-/?-isoRMN and 7-0-daunosaminyl-a-CTN, 
Isolation and Identification of New Compounds
To obtain the new compounds 2a, 2b, 4a and 5a, a large scale-bioconversion was carried out using a 30-liter jar fermenter containing 15liters of the growing culture. The amount of added substrate aglycone (£-isoRMN, /?-isoRMN or a-CTN) was 600 mg. The byconversion was stopped after 4-day cultivation.
The broth was centrifuged and the mycelial pellets were extracted with acetone. The products were recovered finally as crude powder from the acetone extract and then purified according to the same procedure as shown in Fig. 1 . As a result, pure 2a (6.9mg) and 2b (3.3mg) with trace amount of 2c were obtained by bioconversion of £-isoRMN, and pure 4a (42mg) and 5a (58mg) by bioconversion of jS-isoRMN and a-CTN, respectively. TLCanalysis of aglycone and sugar after acid hydrolysis revealed that aglycones of 2a, 4a and 5a were g-isoRM-N, /?-isoRMN and a-CTN, respectively, by comparison with Rf values of authentic samples, and that the sugars were all L-daunosamine in terms ofRfvalue (0.35) and a spot color of white Table 2 . In mass spectra, their molecular ion peaks coincided with the calculated molecular weights of the proposed molecular formulas. UVand IR spectra of2a, 4a and 5a were almost identical to those of their substrate aglycones, but the IR spectrum of2b indicated the absence ofester carbonyl group (1725 cm" 1) which is present in the substrate e-isoRMN. Their *H and 13C NMRchemical shift assignments are shown in Tables 3 and 4 , respectively. *H and 13C NMRchemical shifts of 2a, 4a and 5a revealed that they were the daunosaminyl body of £-isoRMN, jft-isoRMN and oc-CTN, respectively. XHand 13C NMRchemical shifts of 2b lacked those assigned for a carbomethoxy group at C-10 as compared with those of2a, indicating that 2b is decarbomethoxy derivative of 2a. The sugar linkage sites were all determined to be at C-7 since their chemical shifts at C-7 in 13C NMRshifted to lower field about 6~9ppm compared with those of their corresponding aglycones.8>9) The sugar linkage site of 5a was further confirmed by a technique of gated long range selective proton decoupling in which a long range coupling between l'-H and C-7 was observed. The small coupling constants (/=~4 Hz) of their anomeric protons indicate that the configuration of the glycosidic bonds are a. Thus, these new compounds were found to be l-hydroxy-D788-6 (2a), l-hydroxy-D788-ll (2b), l-hydroxy-D788-7 (4a) and 6-deoxy-D788-7 (5a) as illustrated in Fig. 2 . Antitumor Activity In Vitro and In Vivo In vitro antitumor effect of new compoundswas examinedby assaying their inhibitory activities against the cell growth and nucleic acid synthesis of cultured L1210 cells. The corresponding 1-dehydroxy or TV-dimethyl analogs were also tested for comparison. The results are shownin Table 5 . Growth inhibitory activities of4a and 5a were very strong, but those of2a and 2b were moderate. Activity comparison with their TV-dimethyl analogs showed that loss of TV-dimethyl group caused a significant decrease in the growth inhibitory activity. As reported previously7) and also cited in Table 5 , one exception was observed between 3a (D788-7) and its TV-dimethyl analog (betaclamycin T). Concerning the inhibitory activity on nucleic acid synthesis, these new compounds exhibited a greater effect on inhibition of DNAsynthesis than RNA synthesis as compared with their TV-dimethyl derivatives. Especially, 2b and 5a inhibited DNAsynthesis more greatly than RNAsynthesis.
Antitumor effects in vivo of4a and 5a were examined against mice ip inoculated with leukemic L1210 cells. The drugs were administered daily ip from day 1 to day 10. 4a and 5a had a maximumantitumor activity of 188 and 158% (T/C) at optimum doses of 0.32 and 0.08mg/kg/day, respectively. In a similar experiment, TV-dimethyl derivatives of 4a and 5a (obelmycin A and yellamycin A) and oxaunomycin exhibited a T/C % of 155, 169 and 200 at optimum doses of 2.5, 0.39 and 0.06mg/kg/day, respectively. The intensely potent antitumor activity of oxaunomycin (7-0-daunosaminyl-/?-RMN) led us to obtain other similar RMN-typeanthracyclines such as 7-<9-daunosaminyl-/?-isoRMN and 7-0-daunosaminyl-a-CTN. For their preparation we tried to apply a bioconversion method using a DRN-nonproducing mutant. Wehave found that a pigment-less nonproducing mutant of DRN-producing Streptomyces coeruleorubidus converted the exogenously added s-RMNand AKNto DRNin the growing culture.12) This bioconversion included a daunosaminylation of the added aglycone and further biosynthetic modifications on the aglycone level toward DRN.Therefore, use of bioconvertant which had a limited or no activity on the biosynthetic modification of aglycone moiety was necessary to achieve selective daunosaminylation. For this purpose, we employed a DRN-nonproducing mutant strain OXA-4which was derived from a newly isolated baumycin producer. This strain had genetic blockages at the biosynthetic steps of decaketide formation and 10-decarboxylation of a precursor metabolite D788-1. As shown in Table 1 , it was found that this strain produced only 7-0-daunosaminyl-/?-RMN from /J-RMN without production of any other metabolites. Thus, we were able to obtain 7-0-daunosaminyl-/?-isoRMN (4a) and -a-CTN (5a) by bioconversion of /?-isoRMN and a-CTN with strain OXA-4. As we have found that the glucosidation of oc-CTN, but not /J-isoRMN, with an aclarubicin-nonproducing mutant of Streptomyces galilaeus takes place at a C-10 hydroxyl group,6) it is interesting that the glycosidation with strain OXA-4occurs at a C-7 hydroxyl group.
1-Hydroxyoxaunomycin (4a) and 6-deoxyoxaunomycin (5a) thus obtained exerted their optimum antitumor activities in vivo at a 5-fold or more lower dose as compared with their TV-dimethyl derivatives, obelmycin A and yellamycin A, respectively. However, the potent antitumor activities seen in vitro and in vivo with oxaunomycin were not observed with these new 1-hydroxy and 6-deoxy analogs.
